Integrating Biosimilars Into Oncology Practice: Implications for the Advanced Practitioner

about

Integrating Biosimilars Into Oncology Practice: Implications for the Advanced Practitioner

Item

http://www.wikidata.org/entity/Q58585594

description

article

@en

wetenschappelijk artikel

@nl

name

Integrating Biosimilars Into O ...... for the Advanced Practitioner

@en

Integrating Biosimilars Into O ...... for the Advanced Practitioner

@nl

type

Item

label

Integrating Biosimilars Into O ...... for the Advanced Practitioner

@en

Integrating Biosimilars Into O ...... for the Advanced Practitioner

@nl

prefLabel

Integrating Biosimilars Into O ...... for the Advanced Practitioner

@en

Integrating Biosimilars Into O ...... for the Advanced Practitioner

@nl

P1476

Integrating Biosimilars Into O ...... for the Advanced Practitioner

@en

P2093

Christopher J Campen

http://www.w3.org/2001/XMLSchema#string

P2860

A clinician's guide to biosimilars in oncology

Mechanisms of adverse drug reactions to biologics.

Comparative immunogenicity assessment: a critical consideration for biosimilar development.

Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.

Current Status of Biosimilars in Oncology.

Safety and efficacy of biosimilars in oncology.

Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community.

P304

688-699

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P698

30333932

http://www.w3.org/2001/XMLSchema#string

P932

6188098

http://www.w3.org/2001/XMLSchema#string